EDP Sciences logo
Web of Conferences logo
Search
Menu
All issues Volume 348 (2026) EPJ Web Conf., 348 (2026) 01002 References
Open Access
Issue
EPJ Web Conf.
Volume 348, 2026
3rd International Conference on Innovations in Molecular Structure & Instrumental Approaches (ICMSI 2026)
Article Number 01002
Number of page(s) 15
Section Life Science
DOI https://doi.org/10.1051/epjconf/202634801002
Published online 21 January 2026
  1. Cummings, Paul S, Aisen, Bruno B, Lutz F; Drug development in Alzheimer's disease: the path to 2025. Alzheimer's Research & Therapy. 8, 39 (2016) https://doi.org/10.1186/s13195-016-0207-9. [Google Scholar]
  2. C. Kwon, Yin Rui L, Lynnett O, Michael G; Alzheimer's Disease: Key Insights from Two Decades of Clinical Trial Failures; Journal of Alzheimer's Disease. 87(1), 83–100 (2022) https://doi.org/10.3233/jad-215699 [Google Scholar]
  3. Mehta D, Jackson R, Paul G, Shi J, Sabbagh M. Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015. Expert Opin Investig Drugs. 2017;26(6):735–739. https://doi.org/10.1080/13543784.2017.1323868 [Google Scholar]
  4. Passeri E, Elkhoury K, Morsink M, Broersen K, Linder M, Tamayol A, Malaplate C, Yen FT, Arab-Tehrany E. Alzheimer's disease: Treatment strategies and their limitations. Int J Mol Sci. 2022;23(22):13954. https://doi.org/10.3390/ijms232213954 [Google Scholar]
  5. Cummings J. Lessons learned from Alzheimer disease: Clinical trials with negative outcomes. Clin Transl Sci. 2018;1(2):1–6. https://doi.org/10.1111/cts.12491 [Google Scholar]
  6. Pardridge WM. Alzheimer's disease drug development and the problem of the blood-brain barrier. Alzheimers Dement. 2009;5(5):427–432. https://doi.org/10.1016/j.jalz.2009.06.003 [Google Scholar]
  7. Zeng Y, Liu B, Zhou L, Zeng W, Tian X, Jiang J, Dai D. Safety issues of donepezil combined with memantine in the Alzheimer's disease population: Real-world pharmacovigilance. Expert Opin Drug Saf. 2025;15(4): 1–11. https://doi.org/10.3390/molecules29225314 [Google Scholar]
  8. Filippi M, Cecchetti G, Spinelli EG, Vezzulli P, Falini A, Agosta F. Amyloid-Related Imaging Abnormalities and ß-Amyloid-Targeting Antibodies: A Systematic Review. JAMA Neurol. 2022;79(3), 291–304. [Google Scholar]
  9. Sharma A, Rudrawar S, Bharate SB, Jadhav HR. Recent advancements in the therapeutic approaches for Alzheimer's disease treatment: Current and future perspective. RSC Med Chem. 2025;16(2):652–693. https://doi.org/10.3390/ijms26083915 [Google Scholar]
  10. Gebril HM, Aryasomayajula A, de Lima MRN, Uhrich KE, Moghe PV. Nanotechnology for microglial targeting and inhibition of neuroinflammation underlying Alzheimer's pathology. Transl Neurodegener. 2024;13(1). https://doi.org/10.1186/s40035-023-00393-7 [Google Scholar]
  11. Manap AS, Almadodi R, Sultana S, Sebastian MG, Kavani KS, Lyenoug VE, Shankar A. Alzheimer's disease: A review on current trends in effective diagnosis and therapeutics. Front Aging Neurosci. 2024;9(16):1429211. https://doi.org/10.3389/fnagi.2024.1429211 [Google Scholar]
  12. Frozza RL, Lourenco MV, De Felice FG. Challenges for Alzheimer's disease therapy: Insights from novel mechanisms beyond memory defects. Front Neurosci. 2018;12(3). https://doi.org/10.3389/fnins.2018.00037. [Google Scholar]
  13. Yiannopoulou KG, Papageorgiou SG. Current and future treatments in Alzheimer disease: An update. J Cent Nerv Syst Dis. 2020;12(11). https://doi.org/10.1177/1179573520907397 [Google Scholar]
  14. Rabinovici GD, La Joie R. Amyloid-targeting monoclonal antibodies for Alzheimer disease. Jama. 2023;330(6), 507–509. https://doi.org/10.1001/jama.2023.11703 [Google Scholar]
  15. Passeri E, Elkhoury K, Morsink M, Broersen K, Linder M, Tamayol A, Malaplate C, Yen FT, Arab-Tehrany E. Alzheimer's disease: Treatment strategies and their limitations. Int J Mol Sci. 2022;23(22):13954. https://doi.org/10.3390/ijms232213954. [Google Scholar]
  16. Paton J, Johnston K, Katona C, Livingston G. What causes problems in Alzheimer's disease: attributions by caregivers. A qualitative study. International journal of geriatric psychiatry. 2004 Jun;19(6):527–32. https://doi.org/10.1002/gps. 1118 [Google Scholar]
  17. Alva G, Cummings JL. Relative tolerability of Alzheimer's disease treatments. Psychiatry (Edgmont). 2008 Nov;5(11):27. https://pmc.ncbi.nlm.nih.gov/articles/PMC2695725/ [Google Scholar]
  18. Kim CK, Lee YR, Ong L, Gold M, Kalali A, Sarkar J. Alzheimer's disease: Key insights from two decades of clinical trial failures. J Alzheimers Dis. 2022;87(1):83–100. https://doi.org/10.3233/jad-215699 [Google Scholar]
  19. Brawley EC. Designing for Alzheimer's disease: Strategies for creating better care environments. New York: John Wiley & Sons; 1997. https://doi.org/10.1177/1533317509358885 [Google Scholar]
  20. Zhang M, Mi N, Ying Z, Lin X, Jin Y. Advances in the prevention and treatment of Alzheimer's disease based on oral bacteria. Front Psychiatry. 2023;14:1291455. https://doi.org/10.3389/fpsyt.2023.1291455 [Google Scholar]
  21. Itzhaki RF, Golde TE, Heneka MT, Readhead B. Do infections have a role in the pathogenesis of Alzheimer disease. Nature Reviews Neurology. 2020 Apr;16(4):193–7. https://doi.org/10.1038/s41582-020-0323-9 [Google Scholar]
  22. Batool A, Kamal MA, Rizvi S, Rashid S. Topical discoveries on multi-target approach to manage Alzheimer's disease. Curr Drug Metab. 2018;19(8):704–713. https://doi.org/10.2174/1389200219666180305152553 [Google Scholar]
  23. Cheong SL, Tiew JK, Fong YH, Leong HW, Chan YM, Chan ZL, Kong EW. Current pharmacotherapy and multi-target approaches for Alzheimer's disease. Pharmaceuticals. 2022;15(12):1560. https://doi.org/10.3390/ph15121560 [Google Scholar]
  24. Agis-Torres A, Sollhuber M, Fernandez M, Sanchez-Montero JM. Multi-target-directed ligands and other therapeutic strategies in the search for a real solution for Alzheimer's disease. Curr Neuropharmacol. 2014;12(1):2–36. https://doi.org/10.2174/1570159x113116660047. [Google Scholar]
  25. Grosso C, Silva A, Delerue-Matos C, Barroso MF. Single and multitarget systems for drug delivery and detection: Up-to-date strategies for brain disorders. Pharmaceuticals. 2023;16(12):1721. https://doi.org/10.3390/ph16121721 [Google Scholar]
  26. Katsoulaki EE, Dimopoulos D, Hadjipavlou-Litina D. Multitarget compounds designed for Alzheimer, Parkinson, and Huntington neurodegeneration diseases. Pharmaceuticals. 2025;18(6):831. https://doi.org/10.3390/ph18060831 [Google Scholar]
  27. Kondej M, Stepnicki P, Kaczor AA. Multi-target approach for drug discovery against schizophrenia. Int J Mol Sci. 2018;19(10):3105. https://doi.org/10.3390/ijms19103105. [Google Scholar]
  28. Vediya P, Zalavadiya I, Trivedi U, Mehta D, gopal Reddy BR. Comprehensive Review on Role of Nanoparticles in Gene Therapy. InE3S Web of Conferences 2025 (Vol. 619, p. 04009). https://doi.org/10.1051/e3sconf/202561904009. [Google Scholar]
  29. Zalavadiya I, Vediya P, Trivedi U, Asif M. "Nanoparticles as Vaccine Heroes: Unveiling Their Impact"-A Review. InE3S Web of Conferences 2025 (Vol. 619, p. 04001). https://doi.org/10.1051/e3sconf/202561904001. [Google Scholar]
  30. Vaghela UP, Sheth DB, Jani B, Ajudia R, Bera A, Vediya P, Pandya S, Kanabar VB, Parmar G. A comprehensive investigation on female Wistar rats examining the therapeutic potential of Pueraria tuberosa on letrozole-induced Polycystic ovarian syndrome. Egyptian Pharmaceutical Journal. 2024 Oct 1;23(4):595–606. [Google Scholar]
  31. Trivedi U, Vediya P, Zalavadiya I, Kumar BP. Nanotechnology's Impact on Revolutionizing Healthcare and Drug Delivery in the 21st Century. InE3S Web of Conferences 2025 (Vol. 619, p. 04004). https://doi.org/10.1051/e3sconf/202561904004. [Google Scholar]
  32. Vaghela UP, Vadera D, B, Rathod A, Chhayani D, Hirpara K, Parekh K, Kanabar V, Vediya P, Gohil D. Anticataract Effects of Methanol Extract of Ocimum sanctumL. Leaf on In VitroGlucose-induced Goat Eye Lens Model. development.;9:10. 10.18311/jnr/2025/48625 [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.